Senti Bio Awarded Funding from National Cancer Institute (NCI) to Support Development of Logic Gated Allogeneic CAR-NK Cell Therapy SENTI-202 to Treat Acute Myeloid Leukemia SOUTH SAN FRANCISCO, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Senti Bio, a leading gene circuit company, today announced that it has been awarded a Small Business Innovation Research (SBIR)...